Godelieve A.M. Tytgat

Author

Also Known As

G A M Tytgat, G A Tytgat, G Tytgat, G. A. M. Tytgat, G. A. Tytgat, G.A.M. Tytgat, Godelieve A M Tytgat, Godelieve A Tytgat, Godelieve A. M. Tytgat, Godelieve A. Tytgat

194

Publications

5.2K

Citations

H-Index

Concepts

All Affiliations

Princess Máxima Center Emma Kinderziekenhuis Amsterdam UMC Location University of Amsterdam University of Amsterdam Sanquin

About

Godelieve A.M. Tytgat is an author at Princess Máxima Center specializing in medicine, pathology, and neuroblasts.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	20	2.3K
2	Cell Biology	7	7	1.9K
3	Health Sciences	5	5	163
4	Biochemistry	1	1	58
5	Cellular Therapies	1	1	36

Godelieve A.M. Tytgat

Publications

4.2K

Citations

H-Index

Page 1

	Year	Citations
Neuroblastoma is composed of two super-enhancer-associated differentiation states Tim van Groningen, Jan Köster, Linda J. Valentijn, Nature Genetics Neuro-oncologySuper-enhancer-associated Differentiation StatesDevelopmental BiologyEpendymaNeuroblasts	2017	554
Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations Thomas F. Eleveld, Derek A. Oldridge, Virginie Bernard, Nature Genetics Receptor Tyrosine KinasePathologyNeuroblastsTumor SuppressorCancer Genetics	2015	543
TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors Linda J. Valentijn, Jan Köster, Danny A. Zwijnenburg, Nature Genetics Tumoral PathologyTumor InnervationMedicinePathologyNeuroblasts	2015	375
An organoid biobank for childhood kidney cancers that captures disease and tissue heterogeneity Camilla Calandrini, Frans Schutgens, Rurika Oka, Nature Communications	2020	301
Mutations in the SIX1/2 Pathway and the DROSHA/DGCR8 miRNA Microprocessor Complex Underlie High-Risk Blastemal Type Wilms Tumors Jenny Wegert, Naveed Ishaque, Romina Vardapour, Cancer Cell GeneticsMolecular GeneticsSmall RnaCancer GeneticsMicrorna Detection	2015	300
Gain of 1q As a Prognostic Biomarker in Wilms Tumors (WTs) Treated With Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study Tasnim Chagtai, Christina Zill, Linda Dainese, Journal of Clinical Oncology	2016	130
<i>PHOX2B</i> Is a Novel and Specific Marker for Minimal Residual Disease Testing in Neuroblastoma Janine Stutterheim, Annemieke Gerritsen, Lily Zappeij‐Kannegieter, Journal of Clinical Oncology	2008	97
Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy Judith Wienke, Lindy L. Visser, Waleed M. Kholosy, Cancer Cell	2024	79
Detecting Minimal Residual Disease in Neuroblastoma: The Superiority of a Panel of Real-Time Quantitative PCR Markers Janine Stutterheim, Annemieke Gerritsen, Lily Zappeij‐Kannegieter, Clinical Chemistry	2009	76
Catecholamines profiles at diagnosis: Increased diagnostic sensitivity and correlation with biological and clinical features in neuroblastoma patients I.R.N. Verly, André B. P. Kuilenburg, N. G. G. M. Abeling, European Journal of Cancer Neuro-oncologyNeuroblastoma PatientsNeuroblastsNeuroscienceNeurology	2017	73

Page 1